|
| |
PDL BioPharmaPDL BioPharma is a leader in the discovery, development and marketing of innovative therapies for serious or life-threatening illnesses, commercially focused on the acute care, hospital setting. Our therapeutic emphasis is on the areas of hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer . Developing and commercializing innovative therapies for serious or life-threatening illnesses — this is what PDL BioPharma is all about. With a unique focus on the acute care, hospital-based setting, our research, development and commercial teams are working to bring new therapies to physicians and patients that we hope will improve and save lives. Today, our commercial products — Cardene I.V., Retavase and IV Busulfex — are helping patients with serious medical illnesses, while our research and development teams strive to bring important innovative new therapies to the forefront of tomorrow's patient care.
| Contact Details: |
| 34801 Campus Drive |
| Fremont |
| California |
| 94555 |
| United States of America |
| Tel: | 510-574-1400 |
| Fax: | 510-574-1500 |
| Email: | tpearce@pdl.com |
| WWW: | www.pdl.com/
|
|
Loading...
|
Recent Publications by PDL BioPharma: |  |
Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.
Humanization and modification of the Fc region of anti-human CD3 mAbs have... | 1st August, 2009
| PDL BioPharma 1400 Seaport Blvd Redwood City, CA 94063, USA.
| J Neuroimmunol. 2009 Jul 25;212(1-2):65-73. Epub 2009 May 23.
DOI Direct Link |
Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies.
Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have... | 26th February, 2009
| Research Department, PDL BioPharma, Redwood City, California 94063, USA.
| Immunol Invest. 2009;38(1):76-92.
DOI Direct Link |
NS0 cell damage by high gas velocity sparging in protein-free and cholesterol-free cultures.
Recent developments in high cell density and high productivity fed-batch... | 19th November, 2008
| Process Sciences and Engineering, PDL BioPharma, Inc., 1400 Seaport Blvd,
| Biotechnol Bioeng. 2008 Nov 1;101(4):751-60.
DOI Direct Link |
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
Angiogenesis, the process by which new blood vessels form from existing... | 10th June, 2008
| PDL Biopharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.
| Invest New Drugs. 2008 Feb;26(1):7-12. Epub 2007 Sep 1.
DOI Direct Link |
A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
BACKGROUND: Integrins are important adhesion molecules that regulate tumor... | 29th March, 2008
| Department of Research, PDL Biopharma, Inc,, Fremont, CA 94555, USA.
| J Transl Med. 2007 Nov 27;5:61.
DOI Direct Link |
→View more PDL BioPharma research publications. |
Press Releases on PDL BioPharma:
|
 |
| PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction |
2nd November, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., Nov. 2 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it closed on its previously disclosed $300 million securitization transaction
|
| PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction |
28th October, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., Oct. 28 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has priced a $300 million securitization transaction intended to monetize
|
| PDL BioPharma Announces Third Quarter 2009 Financial Results |
28th October, 2009 |
PDL BioPharma, Inc. |
-- The failure of licensees to comply with existing license agreements,
including any failure to pay royalties due.
Other factors that may cause PDL's actual results to differ
|
| PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009 |
27th October, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., Oct. 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer,
|
| PDL BioPharma Reschedules Third Quarter 2009 Financial Results Conference Call for 8:30 a.m. ET on October 28, 2009 |
27th October, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., Oct. 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold its conference call and webcast at 8:30 a.m. Eastern Time
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 809 times since April 2007, the link to the organisation's website has been followed 83 times Recent Search Terms used to find this page: special dividend pdli november 2009 | 1 510 574 1400 | PDLI october 17th 2009 | pdl biopharma email | PDL biopharma | john mclaughlin pdl pharma email address | pdl biopharma | PDL BioPharma | PDL BioPharma Inc. | PDL | . Search for more companies in Fremont Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for PDL BioPharma |
